DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

Contact Supplier

Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

Synopsis

ACTIVE PHARMA INGREDIENTS

API Suppliers

USDMF

CEP/COS

JDMF

EU WC

KDMF

NDC API

VMF

Listed Suppliers

API REF. PRICE (USD/KG)

$ 0

MARKET PLACE

API

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

FDF Dossiers

FDA Orange Book

Europe

Canada

Australia

South Africa

Listed Dossiers

0 DRUGS IN DEVELOPMENT

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

EDQM

USP

Others

PATENTS & EXCLUSIVITIES

US Patents

US Exclusivities

Health Canada Patents

DIGITAL CONTENT

Data Compilation #PharmaFlow

Stock Recap #PipelineProspector

Weekly News Recap #Phispers

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid (USD)

Annual Reports (USD Million)

Finished Drug Prices

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown

Click the button for full data set

Also known as: 912444-00-9, Abt-888, Abt 888, Abt-888 (veliparib), Veliparib free base, Abt888

Molecular Formula

C₁₃H₁₆N₄O

Molecular Weight

244.29 g/mol

InChI Key

JNAHVYVRKWKWKQ-CYBMUJFWSA-N

FDA UNII

01O4K0631N

Veliparib is a poly(ADP-ribose) polymerase (PARP) -1 and -2 inhibitor with chemosensitizing and antitumor activities. With no antiproliferative effects as a single agent at therapeutic concentrations, ABT-888 inhibits PARPs, thereby inhibiting DNA repair and potentiating the cytotoxicity of DNA-damaging agents. PARP nuclear enzymes are activated by DNA single or double strand breaks, resulting in the poly(ADP-ribosyl)ation of other nuclear DNA binding proteins involved in DNA repair; poly(ADP-ribosyl)ation contributes to efficient DNA repair and to survival of proliferating cells exposed to mild genotoxic stresses as induced by as oxidants, alkylating agents or ionizing radiation.

1 2D Structure

Veliparib

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

2-[(2R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide

2.1.2 InChI

InChI=1S/C13H16N4O/c1-13(6-3-7-15-13)12-16-9-5-2-4-8(11(14)18)10(9)17-12/h2,4-5,15H,3,6-7H2,1H3,(H2,14,18)(H,16,17)/t13-/m1/s1

2.1.3 InChI Key

JNAHVYVRKWKWKQ-CYBMUJFWSA-N

2.1.4 Canonical SMILES

CC1(CCCN1)C2=NC3=C(C=CC=C3N2)C(=O)N

2.1.5 Isomeric SMILES

C[C@@]1(CCCN1)C2=NC3=C(C=CC=C3N2)C(=O)N

2.2 Other Identifiers

2.2.1 UNII

01O4K0631N

2.3 Synonyms

2.3.1 MeSH Synonyms

1. 2-((r)-2-methylpyrrolidin-2-yl)-1h-benzimidazole-4-carboxamide

2. 2-(2-methylpyrrolidin-2-yl)-1h-benzimidazole-4-carboxamide

3. Abt 888

4. Abt-888

5. Abt888

2.3.2 Depositor-Supplied Synonyms

1. 912444-00-9

2. Abt-888

3. Abt 888

4. Abt-888 (veliparib)

5. Veliparib Free Base

6. Abt888

7. (r)-2-(2-methylpyrrolidin-2-yl)-1h-benzo[d]imidazole-4-carboxamide

8. 2-[(2r)-2-methylpyrrolidin-2-yl]-1h-benzimidazole-4-carboxamide

9. 2-[(2r)-2-methyl-2-pyrrolidinyl]-1h-benzimidazole-7-carboxamide

10. Chebi:62880

11. 2-[(r)-2-methylpyrrolidin-2-yl]-1h-benzimidazole-4-carboxamide

12. Parp-1 Inhibitor Abt-888

13. 912444-00-9 (free Base)

14. 01o4k0631n

15. 2-[(2r)-2-methylpyrrolidin-2-yl]-1h-benimidazole-4-

16. (2r)-2-(7-carbamoyl-1h-benzimidazol-2-yl)-2-methylpyrrolidinium

17. 2-((r)-2-methylpyrrolidin-2-yl)-1h-benzimidazole-4-carboxamide

18. Veliparib (abt-888)

19. (r)-2-(2-methylpyrrolidin-2-yl)-1h-benimidazole-4-carboxamide (veliparib)

20. 2-((2r)-2-methyl-2-pyrrolidinyl)-1h-benzimidazole-7-carboxamide

21. 2-((2r)-2-methylpyrrolidin-2-yl)-1h-benzimidazole-4-carboxamide

22. Nsc-737664

23. Veliparib [usan:inn]

24. Mfcd16661059

25. Unii-01o4k0631n

26. 78p

27. Veliparib [inn]

28. Veliparib [jan]

29. Veliparib [usan]

30. Abt888 (free Base)

31. (r)-2-(2-methylpyrrolidin-2-yl)-1h-benzo[d]imidazole-7-carboxamide

32. Veliparib [who-dd]

33. Benzimidazole Carboxamide, 3a

34. Mls006010184

35. Veliparib (jan/usan/inn)

36. Schembl422318

37. Chembl506871

38. Gtpl7417

39. Bdbm27135

40. Abt-695

41. Dtxsid90238456

42. Ex-a001

43. Bdbm209932

44. Veliparib (abt-888 Hydrochloride)

45. 2-[(2r)-2-methylpyrrolidin-2-yl]-1h-1,3-benzodiazole-4-carboxamide

46. Nsc737664

47. Nsc752840

48. S1004

49. Zinc84610155

50. Akos015951440

51. Akos017343746

52. Ccg-264771

53. Cs-0076

54. Db07232

55. Ex-7209

56. Nsc 737664

57. Nsc-752840

58. Sb16480

59. Ncgc00250404-01

60. Ncgc00250404-15

61. Ac-23330

62. As-19397

63. Hy-10129

64. Smr004701290

65. Abt-888 (veliparib, Nsc 737664)

66. A24888

67. D09692

68. A 861695

69. A-861695

70. J-505211

71. Q7919041

72. Brd-k87142802-001-02-7

73. 1h-benzimidazole-4-carboxamide, 2-((2r)-2-methyl-2-pyrrolidinyl)-

74. 2-[(2r)-2-methylpyrrolidin-2-yl]-1h-benimidazole-4-carboxamide

75. 2-[(2r)-2-methylpyrrolidin-2-yl]-1h-benzimidazole-7-carboxamide

76. 2-[(r)-2-methylpyrrolidin-2-yl]-1h-benzimidazole-4-carboxamide;

77. 1h-benzimidazole-7-carboxamide, 2-((2r)-2-methyl-2-pyrrolidinyl)-

2.4 Create Date

2006-12-11

3 Chemical and Physical Properties

Molecular Formula	C₁₃H₁₆N₄O
Molecular Weight	244.29 g/mol
XLogP3	0.5
Hydrogen Bond Donor Count	3
Hydrogen Bond Acceptor Count	3
Rotatable Bond Count	2
Exact Mass	244.13241115 g/mol
Monoisotopic Mass	244.13241115 g/mol
Topological Polar Surface Area	83.8 Å²
Heavy Atom Count	18
Formal Charge	0
Complexity	348
Isotope Atom Count	0
Defined Atom Stereocenter Count	1
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	1

4 Drug and Medication Information

4.1 Drug Indication

Treatment of fallopian tube cancer , Treatment of ovarian cancer , Treatment of peritoneal carcinoma

Treatment of lung carcinoma (small cell and non-small cell carcinoma)

Treatment of breast cancer

Treatment of high-grade glioma

5 Pharmacology and Biochemistry

5.1 MeSH Pharmacological Classification

Poly(ADP-ribose) Polymerase Inhibitors

Chemicals and drugs that inhibit the action of POLY(ADP-RIBOSE)POLYMERASES. (See all compounds classified as Poly(ADP-ribose) Polymerase Inhibitors.)

5.2 ATC Code

L - Antineoplastic and immunomodulating agents

L01 - Antineoplastic agents

L01X - Other antineoplastic agents

L01XK - Poly (adp-ribose) polymerase (parp) inhibitors

L01XK05 - Veliparib

ABOUT THIS PAGE

Find Veliparib manufacturers, exporters & distributors on PharmaCompass

Veliparib

ACCESS ALL DATA

Browse all information

CHEMISTRY

Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

API REF. PRICE (USD/KG)

$ 0

MARKET PLACE

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

0 DRUGS IN DEVELOPMENT

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

PATENTS & EXCLUSIVITIES

DIGITAL CONTENT

GLOBAL SALES INFORMATION

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

What are you looking for?